Agentic Documentation Workspace for Life Sciences
Agentic Documentation Workspace for Life Sciences
Cut Documentation Effort up to 75%,
Bring Your Products to Market Faster
Zenopsys is the AI-native documentation workspace built for life sciences. It enables teams to author, review, and deliver high-quality drafts of technical and regulatory documents across the entire product lifecycle - from R&D and regulatory submissions to post-approval lifecycle management.
Book a Demo
Collaborating with Global Life Sciences Leaders
Speed, Quality, Scale - All in One AI Platform
10× Faster Documentation Cycles
From source data to submission-ready draft, end-to-end, across every document type and use case
Near Zero Errors
AI review agents continuously catch gaps, inconsistencies and issues before they reach submission
Improve First-Cycle Approval Rates
Consistent, high quality dossiers that learn from regulator’s requirements and withstand AI-powered reviews
Expand Without Growing your Team
Launch new products and expand across geographies without increasing headcount
10x Faster Documentation Cycles
From source data to submission-ready draft, end-to-end, across every document type and use case
Near Zero Errors
AI review agents continuously catch gaps, inconsistencies and issues before they reach submission
Improve First-Cycle Approval Rates
Consistent, high-quality dossiers that learn from regulator’s requirements and withstand AI-powered reviews
Expand Without Growing your Team
Launch new products and expand across geographies without increasing headcount
Built for Every Team Across the Drug Development Lifecycle
Built for Every Team Across the Drug Development Lifecycle
Built for Every Team Across the Drug Development Lifecycle
Research & Development
Clinical
Regulatory
Quality
Research & Development
Clinical
Regulatory
Quality
Research & Development
Clinical
Regulatory
Quality
Capabilities that Accelerate Your Regulatory and Technical Documentation
Document Authoring
With a single click, turn source data into structured, submission-ready technical documents in minutes.
Virtual Regulator
AI-powered review that thinks, checks, and guides teams to identify gaps like a real FDA regulator.
Deep Research Assistant
Chat with the largest guidance, webinar repository & internal databases. The only AI assistant a regulatory professional will ever need!
End-to-End Traceability
Maintain clear traceability across source data, document sections, and revisions so reviewers can quickly understand what changed, why, and where - accelerating review cycles.
Refine with Al
Create tables, lists, figures, and apply document styles with ease using our built-in “Refine with AI”. Eliminate the lengthy manual work and last-minute rework!
Built-In Collaboration
Collaborate in real time with shared access, comments, and version control. Keep teams aligned across drafting, review, and preparation stages without version confusion or email-based reviews.
Proven in Live Regulatory Submissions
Proven in Live
Regulatory Submissions
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Enterprise Grade Security From Day 1
Enterprise Grade Security From Day 1
Zenopsys Cloud or Bring Your Own Cloud
Zenopsys Cloud or Bring Your Own Cloud
Zero Data Storage and Zero Training
Zero Data Storage and Zero Training
IP Whitelisting and Network Access Control
IP Whitelisting and Network Access Control
Single Tenant Isolated Deployment
Single Tenant Isolated Deployment
Built-In Role Based Access Control
Built-In Role Based Access Control
Network Isolation
Network Isolation
Encryption at Rest and In Transit
Encryption at Rest and In Transit
Transforming Documentation across Life Sciences
Biotech
Pharma
CRDMOs
Consultants
Backed by Leaders from BioPharma
Anand Ekambaram
Ex-VP, Merck & BMS (USA)
Advisor
Dr. Jayanth Sridhar
Ex-CEO, Dr. Reddy’s Biologics
Investor & Advisor
Venkat Kamalakar
CEO, Marksans Pharma, EU
Investor & Advisor
Dr. Mahesh Bhalgat
CEO, Veeda Life Sciences
Advisor
Srinivas Rao Aluri
Ex-MD, Morgan Stanley PE
Advisor
Vinod Nuguri
Head, Reg Affairs, Wishmen LifeSciences
Advisor
Funded by Leading Venture Capital Firms
Coverage
Built for Global Submissions
Zenopsys supports submissions across all major regulatory agencies and markets
Ready to Accelerate Your Next Product Launch?
Book a Demo
Testimonials
Proven in Live
Regulatory Submissions
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Dr. Jayanth Sridhar
Ex. CEO, Biologics, Dr. Reddy's
“As a CEO, if I can accelerate time to market by even 2 months that's a huge impact on my top-line. In an extremely competitive biosimilars and generics market, what Zenopsys has built will be a game changer.”
Anand Ekambaram
Ex. VP, Merck, BMS (USA)
“At Merck, it took us 3-4 months of back and forth reviews on all CMC, Clinical documents to identify any gaps or inconsistencies and get submission ready. It amazes me how Zenopsys has built an AI reviewer that eliminates all of that effort with real-time quality checks.”
Surya Namburi,
Director, iPharMed (UK Based Regulatory Consulting Firm)
"Zenopsys cut our Module 2.4, 2.5 authoring time from 4 weeks to under 2 days, and the output went into our submission with minimal edits. The traceability gave our QA team confidence we'd never had with manual drafts."
Coverage
Built for Global Submissions
Zenopsys supports submissions across all major regulatory agencies & markets
Learn how integration works
Benefits
Outcomes that Redefine Regulatory Efficiency
10× Faster Documentation Cycles
From source data to submission-ready draft, end-to-end, across every document type and use case
Near Zero manual errors
AI review agents continuously catch gaps, inconsistencies and issues before they reach submission
Improve First-Cycle Approval Rates
Consistent, high-quality dossiers that learn from regulator’s requirements and withstand AI-powered reviews
Expand Without Growing your Team
Launch new products and expand across geographies without increasing headcount
Trusted by India's leading Life Sciences Companies
Platform Capabilities
Capabilities that Bring Structure to Regulatory Work
Document Authoring
With a single click, turn source data into structured, submission-ready technical documents in minutes.
Virtual Regulator
AI-powered review that thinks, checks, and guides teams to identify gaps — like a real FDA regulator.
Deep Research Assistant
Chat with the largest guidance, webinar repository & internal databases. The only AI assistant a regulatory professional will ever need!
End-to-End Traceability
Maintain clear traceability across source data, document sections, and revisions so reviewers can quickly understand what changed, why, and where - accelerating review cycles.
Refine with Al
Create tables, lists, figures, and apply document styles with ease using our built-in “Refine with AI”. Eliminate the lengthy manual work and last-minute rework!
Built-In Collaboration
Collaborate in real time with shared access, comments, and version control. Keep teams aligned across drafting, review, and preparation stages without version confusion or email-based reviews.
Industries we support
Supporting Regulatory Work across Life Sciences
Biotech
Pharma
CRDMOs
Consultants
Investors & advisors
Backed by Leaders from BioPharma
Anand Ekambaram
Ex-VP, Merck & BMS (USA)
Advisor
Dr. Jayanth Sridhar
Ex-CEO, Dr. Reddy’s Biologics
Investor & Advisor
Venkat Kamalakar
CEO, Marksans Pharma, EU
Investor & Advisor
Dr. Mahesh Bhalgat
CEO, Veeda Life Sciences
Advisor
Srinivas Rao Aluri
Ex-MD, Morgan Stanley PE
Advisor
Vinod Nuguri
Head, Reg Affairs, Wishmen LifeSciences
Advisor
Funded by Leading Venture Capital Firms
Coverage
Built for Global Submissions
Zenopsys supports submissions across all major regulatory agencies & markets
Ready to Accelerate Your Next Product Launch?
Book a Demo
Platform Capabilities
Capabilities that Bring Structure to Regulatory Work
Document Authoring
With a single click, turn source data into structured, submission-ready technical documents in minutes.
Virtual Regulator
AI-powered review that thinks, checks, and guides teams to identify gaps — like a real FDA regulator.
Deep Research Assistant
Chat with the largest guidance, webinar repository & internal databases. The only AI assistant a regulatory professional will ever need!
End-to-End Traceability
Maintain clear traceability across source data, document sections, and revisions so reviewers can quickly understand what changed, why, and where - accelerating review cycles.
Refine with Al
Create tables, lists, figures, and apply document styles with ease using our built-in “Refine with AI”. Eliminate the lengthy manual work and last-minute rework!
Built-In Collaboration
Collaborate in real time with shared access, comments, and version control. Keep teams aligned across drafting, review, and preparation stages without version confusion or email-based reviews.
Investors & advisors
Backed by Experienced Operators and Domain Experts
Anand Ekambaram
Ex-VP, Merck & BMS (USA)
Advisor
Dr. Jayanth Sridhar
Ex-CEO, Dr. Reddy’s Biologics
Investor & Advisor
Venkat Kamalakar
CEO, Marksans Pharma, EU
Investor & Advisor
Dr. Mahesh Bhalgat
CEO, Veeda Life Sciences
Advisor
Srinivas Rao Aluri
Ex-MD, Morgan Stanley PE
Advisor
Vinod Nuguri
Head, Reg Affairs, Wishmen LifeSciences
Advisor
Funded by leading venture capital firms
Ready to Accelerate Your Next Product Launch?
Book a Demo